Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674867 | 0.95 | NPSR1 (0.39) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL28661871 | 0.95 | NPSR1 (0.39) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL30467245 | 0.95 | NPSR1 (0.39) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL7653830 | 0.91 | SIRT2 (0.38) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL29544944 | 0.86 | SIRT2 (0.49) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL118552 | 0.86 | SIRT2 (0.49) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| Bromide SCHEMBL5514450 | 0.84 | SIRT2 (0.48) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL15769691 | 0.84 | SIRT2 (0.48) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| Fluoride Ion SCHEMBL4594160 | 0.84 | SIRT2 (0.48) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL30056078 | 0.84 | SIRT2 (0.48) | NPSR1TSHRRXFP1SIRT2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926333-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20170327514-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-9732093-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150368270-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-24 | — | — | US | disclosed |
| US-20150252008-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-10 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-9073876-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-07 | — | — | US | disclosed |
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221310-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| WO-2011156751-A2 | IMMUNOGENIC VACCINE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2066636-B1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | NPSR1 21/4885TSHR 654/4885RXFP1 78/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | NPSR1 21/4885TSHR 654/4885RXFP1 78/4885 |
| US-20170327514-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | NPSR1 2481/4885TSHR 2773/4885RXFP1 453/4885 |
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1B, AVPR1A | NPSR1 27/4885TSHR 211/4885RXFP1 141/4885 |
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | NPSR1 2652/4885TSHR 2884/4885RXFP1 210/4885 |
| US-20140221310-A1 | FLAP MODULATORS | FEN1, PGF, PTGIS | NPSR1 3005/4885TSHR 3351/4885RXFP1 552/4885 |
| US-20150368270-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | NPSR1 2481/4885TSHR 2773/4885RXFP1 453/4885 |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1A | NPSR1 270/4885TSHR 2165/4885RXFP1 526/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | NPSR1 2694/4885TSHR 2461/4885RXFP1 303/4885 |
| US-20150252008-A1 | FLAP MODULATORS | FEN1, PGF, PTGIS | NPSR1 3005/4885TSHR 3351/4885RXFP1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.